Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT06443346
Recruiting Observational

Prospective Registry of EoSinophilic esOphagitis

NCT06443346 · tracked via the Priya Life Science Italy tracker
Sponsor
IRCCS San Raffaele
Phase
Observational
Started
2024-06-01
Last updated
2025-07-30

Condition(s) studied

Eosinophilic Esophagitis

Investigational drug(s) / intervention(s)

Eosinophilic Esophagitis

Eosinophilic Esophagitis: Eosinophilic Esophagitis patients with a proper diagnosis

Study summary

This is a prospective registry of all the Eosinophilic Esophagitis (EoE) patients referred to the third level referral centre of San Raffaele Scientific Institute

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Participant is willing and able to give informed consent for participation in the study. 2. The medical product is the standard of care for the patient or the participant is taking the medicinal product according to clinical practice 3. Being diagnosed with EoE as per guidelines of the disease Exclusion Criteria: 1. No clear diagnosis of EoE 2. Not willing to provide informed consent to the inclusion in the registry

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
IRCCS San Raffaele Milan Lombardy Recruiting

More IRCCS San Raffaele trials in Italy

Virtual Reality Rehabilitation in Neck Pain Subjects Recruiting
CT-based Myocardial Characterization (CTMyoC) Recruiting
Protocollo N 2014 - Benign Prostatic Hyperplasia Recruiting
RRMS: Disease PROgression and Myeloid Profiling After Bone Marrow TRANSPLANTation and Second Line Therapies Recruiting
Multidisciplinary Network OSA Code (Obstructive Apnea Syndrome): Digital Operative Model in Public Health for an Early Diagnosis and Therapy Monitoring Recruiting

Other trials for the same condition

PRospective Registry of Esophageal Motility Recruiting
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis Active, not recruiting
National, Multicenter, Retrospective, Prospective Study to Evaluate Pediatric Gastrointestinal Eosinophilic Disorders Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06443346 on ClinicalTrials.gov ↗ ← All trials in Italy